Compare Rigetti Computing Inc (RGTI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rigetti Computing Inc vs Recursion Pharmaceuticals Inc — how do they compare? Rigetti Computing Inc trades at $15.21 (market cap $5.09B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B). The key difference: Rigetti Computing Inc is far larger — about 2.9× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| RGTI | RXRX | |
|---|---|---|
Market Cap | $5.09B | $1.74B |
Sector | Technology | Health |
52-Week High | $56.34 | $6.79 |
52-Week Low | $12.90 | $2.84 |
Enterprise Value | $4.70B | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rigetti Computing (RGTI) trades at $15.81, up 4.01% today, amid recent U.S. government funding news. The stock shows a bearish technical trend with support at $15 and resistance at $17. Fundamentally, the company reports widening losses with a net income margin of -1,787.4% in 2026 and negative cash flows, though revenue grew to $13 million. Analyst sentiment remains bullish with 85.71% buy ratings.
The outlook is speculative, driven by government backing and quantum computing potential, but high execution risks and persistent losses pose significant challenges. Investors should weigh long-term growth prospects against current financial instability and market volatility.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
